Ahead of Market: 10 things that will decide stock market action on Monday

Indian equities posted their steepest weekly fall in seven months as the Sensex and Nifty extended losses amid U.S. visa curbs and drug tariffs. Pharma and IT stocks dragged, while FIIs stayed cautious. Analysts flagged key support at 24,500, with volatility expected around monthly expiry and global uncertainties weighing on sentiment.

Market Trading Guide: Buy Ashok Leyland, sell Dixon on Monday for gains up to 9%

The Nifty extended its losing streak with a sixth consecutive decline, slipping below the 25,000 support level amid broad-based selling, especially in pharma and IT stocks. Analysts warn of further downside if 24,500 breaks, though a recovery remains possible. Stock recommendations include Ashok Leyland, Dr Agarwal’s Health Care, Dixon, and Anant Raj.

From laggards to leaders: PSU Banks outpace private peers in loan growth after 15 years

India’s public sector banks have achieved a remarkable turnaround, with asset quality improvements, disciplined cost management, and strong credit growth driving profitability. PSBs now deliver sustainable returns, with robust capital positions and cleaner balance sheets. SBI and PNB stand out as key beneficiaries, offering attractive investment potential in India’s evolving banking landscape.

Nifty breaks winning streak, traders eye Oct 3 for strong intraday momentum

The Indian equity market ended a three-week winning streak as Nifty50 slipped 2.6%, pressured by global trade tensions, H-1B visa concerns, and persistent foreign outflows. Time-based technical signals indicate potential intraday volatility, emphasizing cautious trading and disciplined risk management for short-term traders amid fluctuating support and resistance levels.